Cyclo Historical Balance Sheet

CYTH Stock

USD 0.98 0.06 5.77%

Trend analysis of Cyclo Therapeutics balance sheet accounts such as Short Long Term Debt Total of 1.2 M, Total Current Liabilities of 10.2 M or Total Stockholder Equity of 5.7 M provides information on Cyclo Therapeutics' total assets, liabilities, and equity, which is the actual value of Cyclo Therapeutics to its prevalent stockholders. By breaking down trends over time using Cyclo Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cyclo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclo Therapeutics is a good buy for the upcoming year.

Cyclo Therapeutics Inventory

251,900

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

About Cyclo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cyclo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Cyclo Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cyclo Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cyclo currently owns. An asset can also be divided into two categories, current and non-current.

Cyclo Therapeutics Balance Sheet Chart

As of now, Cyclo Therapeutics' Total Stockholder Equity is increasing as compared to previous years. The Cyclo Therapeutics' current Accounts Payable is estimated to increase to about 5.9 M, while Property Plant And Equipment Net is projected to decrease to under 708.5 K.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity Capital Lease Obligations

Total Assets

Total assets refers to the total amount of Cyclo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cyclo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cyclo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cyclo Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Capital Lease Obligations

Cyclo Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Cyclo Therapeutics asset purchases. For example, Cyclo Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Cyclo Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from Cyclo Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Total Stockholder Equity is increasing as compared to previous years. The Cyclo Therapeutics' current Accounts Payable is estimated to increase to about 5.9 M, while Property Plant And Equipment Net is projected to decrease to under 708.5 K.

	2022	2024	2025 (projected)
Short and Long Term Debt Total	1.0M	1.2M	1.2M
Total Assets	4.2M	15.2M	16.0M

Short Long Term Debt Total Total Assets

Cyclo Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Current Liab	Short Term Investments	Current Deferred Revenue
Total Assets		0.26	0.79	0.87	-0.13	-0.93	-0.76	0.85	0.98	-0.27	-0.38	0.98	0.62	0.72	-0.26	-0.17	0.61	0.83	0.79	0.99	0.34	-0.28	-0.41	0.6	-0.3	-0.55
Short Long Term Debt Total	0.26		0.49	-0.04	0.65	0.08	-0.43	0.27	0.08	0.54	0.25	0.08	-0.29	0.62	0.37	-0.14	0.52	0.46	0.54	0.16	0.7	-0.22	-0.38	-0.33	-0.24	0.22
Total Current Liabilities	0.79	0.49		0.39	-0.12	-0.6	-0.93	0.96	0.72	-0.3	-0.47	0.72	0.21	0.97	-0.13	-0.19	0.79	0.97	1.0	0.79	0.61	-0.22	-0.2	0.5	-0.26	-0.6
Total Stockholder Equity	0.87	-0.04	0.39		-0.14	-0.93	-0.41	0.51	0.9	-0.2	-0.23	0.9	0.78	0.31	-0.29	-0.06	0.29	0.48	0.38	0.86	0.04	-0.24	-0.44	0.52	-0.24	-0.37
Property Plant And Equipment Net	-0.13	0.65	-0.12	-0.14		0.37	0.29	-0.33	-0.27	0.98	0.69	-0.27	-0.35	-0.04	0.0	0.11	-0.26	-0.23	-0.08	-0.27	0.12	-0.13	-0.1	-0.64	-0.14	0.78
Net Debt	-0.93	0.08	-0.6	-0.93	0.37		0.64	-0.74	-0.98	0.47	0.48	-0.98	-0.74	-0.49	0.29	0.16	-0.47	-0.67	-0.58	-0.95	-0.16	0.21	0.38	-0.71	0.22	0.64
Retained Earnings	-0.76	-0.43	-0.93	-0.41	0.29	0.64		-0.92	-0.71	0.44	0.57	-0.71	-0.3	-0.93	-0.12	0.22	-0.92	-0.98	-0.92	-0.79	-0.73	0.25	0.31	-0.51	0.28	0.74
Accounts Payable	0.85	0.27	0.96	0.51	-0.33	-0.74	-0.92		0.82	-0.48	-0.59	0.82	0.39	0.87	-0.18	-0.24	0.76	0.95	0.94	0.87	0.47	-0.24	-0.15	0.7	-0.27	-0.74
Cash	0.98	0.08	0.72	0.9	-0.27	-0.98	-0.71	0.82		-0.39	-0.45	1.0	0.68	0.62	-0.31	-0.17	0.54	0.77	0.71	0.99	0.23	-0.23	-0.39	0.68	-0.24	-0.61
Non Current Assets Total	-0.27	0.54	-0.3	-0.2	0.98	0.47	0.44	-0.48	-0.39		0.8	-0.39	-0.36	-0.22	0.03	0.12	-0.39	-0.4	-0.25	-0.4	-0.01	-0.14	-0.03	-0.68	-0.14	0.84
Non Currrent Assets Other	-0.38	0.25	-0.47	-0.23	0.69	0.48	0.57	-0.59	-0.45	0.8		-0.45	-0.25	-0.41	0.01	0.02	-0.51	-0.54	-0.42	-0.48	-0.28	-0.18	0.05	-0.6	-0.16	0.71
Cash And Short Term Investments	0.98	0.08	0.72	0.9	-0.27	-0.98	-0.71	0.82	1.0	-0.39	-0.45		0.68	0.62	-0.31	-0.17	0.54	0.77	0.71	0.99	0.23	-0.23	-0.39	0.68	-0.24	-0.61
Net Receivables	0.62	-0.29	0.21	0.78	-0.35	-0.74	-0.3	0.39	0.68	-0.36	-0.25	0.68		0.16	-0.25	-0.07	0.22	0.32	0.2	0.65	-0.15	-0.26	-0.07	0.55	-0.26	-0.45
Common Stock Shares Outstanding	0.72	0.62	0.97	0.31	-0.04	-0.49	-0.93	0.87	0.62	-0.22	-0.41	0.62	0.16		0.0	-0.19	0.84	0.96	0.97	0.71	0.7	-0.18	-0.29	0.34	-0.22	-0.52
Non Current Liabilities Total	-0.26	0.37	-0.13	-0.29	0.0	0.29	-0.12	-0.18	-0.31	0.03	0.01	-0.31	-0.25	0.0		-0.18	0.46	0.02	-0.12	-0.25	0.48	-0.05	-0.33	-0.28	-0.04	0.03
Inventory	-0.17	-0.14	-0.19	-0.06	0.11	0.16	0.22	-0.24	-0.17	0.12	0.02	-0.17	-0.07	-0.19	-0.18		-0.26	-0.21	-0.24	-0.18	0.03	-0.43	0.49	-0.11	-0.43	-0.01
Other Current Assets	0.61	0.52	0.79	0.29	-0.26	-0.47	-0.92	0.76	0.54	-0.39	-0.51	0.54	0.22	0.84	0.46	-0.26		0.89	0.78	0.63	0.79	-0.19	-0.41	0.35	-0.21	-0.62
Other Stockholder Equity	0.83	0.46	0.97	0.48	-0.23	-0.67	-0.98	0.95	0.77	-0.4	-0.54	0.77	0.32	0.96	0.02	-0.21	0.89		0.96	0.84	0.66	-0.24	-0.32	0.53	-0.28	-0.69
Total Liab	0.79	0.54	1.0	0.38	-0.08	-0.58	-0.92	0.94	0.71	-0.25	-0.42	0.71	0.2	0.97	-0.12	-0.24	0.78	0.96		0.78	0.6	-0.23	-0.22	0.48	-0.26	-0.56
Total Current Assets	0.99	0.16	0.79	0.86	-0.27	-0.95	-0.79	0.87	0.99	-0.4	-0.48	0.99	0.65	0.71	-0.25	-0.18	0.63	0.84	0.78		0.33	-0.24	-0.39	0.67	-0.27	-0.65
Short Term Debt	0.34	0.7	0.61	0.04	0.12	-0.16	-0.73	0.47	0.23	-0.01	-0.28	0.23	-0.15	0.7	0.48	0.03	0.79	0.66	0.6	0.33		-0.19	-0.33	-0.07	-0.2	-0.29
Intangible Assets	-0.28	-0.22	-0.22	-0.24	-0.13	0.21	0.25	-0.24	-0.23	-0.14	-0.18	-0.23	-0.26	-0.18	-0.05	-0.43	-0.19	-0.24	-0.23	-0.24	-0.19		-0.32	-0.26	0.99	0.34
Common Stock	-0.41	-0.38	-0.2	-0.44	-0.1	0.38	0.31	-0.15	-0.39	-0.03	0.05	-0.39	-0.07	-0.29	-0.33	0.49	-0.41	-0.32	-0.22	-0.39	-0.33	-0.32		0.13	-0.3	-0.05
Other Current Liab	0.6	-0.33	0.5	0.52	-0.64	-0.71	-0.51	0.7	0.68	-0.68	-0.6	0.68	0.55	0.34	-0.28	-0.11	0.35	0.53	0.48	0.67	-0.07	-0.26	0.13		-0.27	-0.77
Short Term Investments	-0.3	-0.24	-0.26	-0.24	-0.14	0.22	0.28	-0.27	-0.24	-0.14	-0.16	-0.24	-0.26	-0.22	-0.04	-0.43	-0.21	-0.28	-0.26	-0.27	-0.2	0.99	-0.3	-0.27		0.35
Current Deferred Revenue	-0.55	0.22	-0.6	-0.37	0.78	0.64	0.74	-0.74	-0.61	0.84	0.71	-0.61	-0.45	-0.52	0.03	-0.01	-0.62	-0.69	-0.56	-0.65	-0.29	0.34	-0.05	-0.77	0.35

Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	14.2M	19.5M	4.2M	13.2M	15.2M	16.0M
Total Current Liabilities	3.7M	3.8M	3.5M	8.5M	9.7M	10.2M
Total Stockholder Equity	10.5M	15.7M	734.5K	4.8M	5.5M	5.7M
Property Plant And Equipment Net	87.9K	77.2K	56.7K	929.3K	1.1M	708.5K
Net Debt	(12.7M)	(16.4M)	(1.5M)	(8.2M)	(7.4M)	(7.0M)
Retained Earnings	(34.1M)	(48.3M)	(63.8M)	(83.9M)	(75.5M)	(71.7M)
Accounts Payable	3.5M	3.7M	2.2M	4.9M	5.6M	5.9M
Cash	12.8M	16.6M	1.5M	9.2M	10.6M	11.2M
Non Current Assets Total	137.7K	84.5K	56.7K	929.3K	836.4K	696.5K
Non Currrent Assets Other	49.8K	7.3K	(56.7K)	38.3K	34.5K	32.8K
Cash And Short Term Investments	12.8M	16.6M	1.5M	9.2M	10.6M	11.2M
Net Receivables	111.8K	539.1K	55.0K	122.4K	140.7K	106.4K
Common Stock Shares Outstanding	1.6M	6.4M	8.4M	16.3M	18.8M	19.7M
Liabilities And Stockholders Equity	14.2M	19.5M	4.2M	13.2M	15.2M	16.0M
Non Current Liabilities Total	62.9K	18.0K	3.5M	22.5K	25.9K	24.6K
Inventory	237.9K	227.4K	254.5K	254.4K	292.5K	251.9K
Other Current Assets	854.4K	2.1M	4.6M	2.7M	3.1M	3.3M
Other Stockholder Equity	44.5M	64.0M	64.5M	88.6M	101.9M	107.0M
Total Liab	3.7M	3.8M	3.5M	8.5M	9.8M	10.3M
Total Current Assets	14.1M	19.4M	4.2M	12.3M	14.2M	14.9M
Common Stock	477.0	841.0	849.0	2.9K	3.3K	3.6K
Other Current Liab	3.5M	3.7M	1.2M	1.6M	2.6M	2.7M
Net Tangible Assets	936.0K	10.5M	15.7M	734.5K	844.7K	802.5K
Other Assets	129.7K	90.6K	49.8K	7.3K	6.6K	6.2K
Property Plant Equipment	64.6K	87.9K	77.2K	56.7K	65.2K	56.7K
Net Invested Capital	10.6M	15.8M	734.5K	4.8M	5.5M	5.5M
Property Plant And Equipment Gross	87.9K	159.3K	158.2K	1.1M	1.2M	1.3M
Net Working Capital	10.4M	15.6M	677.9K	3.9M	4.4M	5.2M
Capital Stock	477.0	841.0	849.0	2.9K	2.6K	3.5K
Capital Lease Obligations	35.9K	19.2K	0.0	1.0M	1.2M	1.2M

Currently Active Assets on Macroaxis

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications
DIA	SPDR Dow Jones
SPY	SPDR SP 500

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:

How To Invest In Cyclo

Details

Is Cyclo Stock a good investment?

Details

What is Cyclo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.90)

Revenue Per Share

0.032

Quarterly Revenue Growth

(0.53)

Return On Assets

(2.84)

Return On Equity

(226.64)

The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Historical Balance Sheet

Cyclo Therapeutics Inventory

251,900

About Cyclo Balance Sheet Analysis

Cyclo Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Capital Lease Obligations

Cyclo Therapeutics balance sheet Correlations

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclo Therapeutics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Short Term Investments	+ 0.99	Intangible Assets

Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.95	Net Debt
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Net Debt	- 0.93	Total Stockholder Equity